Is VRCI or YGEN more profitable?

Yourgene Health has a net margin of -27.55% compared to Verici Dx's net margin of -223.60%. Yourgene Health's return on equity of -27.06% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets Verici Dx -223.60% -127.57% -26.14% Yourgene Health -27.55% -27.06% -6.71%

Which has higher valuation and earnings, AGL or VRCI?

Verici Dx has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ANGLE £2.62M 2.89 -£21.76M -£4.80 N/A Verici Dx £3.66M 1.40 -£6.56M -£0.90 N/A

Is AGL or VRCI more profitable?

Verici Dx has a net margin of -223.60% compared to ANGLE's net margin of -1,444.04%. Verici Dx's return on equity of -127.57% beat ANGLE's return on equity. Company Net Margins Return on Equity Return on Assets ANGLE -1,444.04% -191.36% -29.89% Verici Dx -223.60% -127.57% -26.14%

Does the media prefer AGL or VRCI?

In the previous week, ANGLE and ANGLE both had 1 articles in the media. ANGLE's average media sentiment score of 0.75 beat Verici Dx's score of -1.58 indicating that ANGLE is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANGLE 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verici Dx 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative

Is GENI or VRCI more profitable?

GENinCode has a net margin of -202.42% compared to Verici Dx's net margin of -223.60%. Verici Dx's return on equity of -127.57% beat GENinCode's return on equity. Company Net Margins Return on Equity Return on Assets GENinCode -202.42% -481.34% -63.99% Verici Dx -223.60% -127.57% -26.14%

Does the media favor GENI or VRCI?

In the previous week, GENinCode had 4 more articles in the media than Verici Dx. MarketBeat recorded 5 mentions for GENinCode and 1 mentions for Verici Dx. GENinCode's average media sentiment score of -0.31 beat Verici Dx's score of -1.58 indicating that GENinCode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GENinCode 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Verici Dx 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative

Is PRM or VRCI more profitable?

Proteome Sciences has a net margin of -61.46% compared to Verici Dx's net margin of -223.60%. Proteome Sciences' return on equity of 23.85% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets Proteome Sciences -61.46% 23.85% -19.25% Verici Dx -223.60% -127.57% -26.14%

Does the media favor PRM or VRCI?

In the previous week, Proteome Sciences and Proteome Sciences both had 1 articles in the media. Proteome Sciences' average media sentiment score of -0.71 beat Verici Dx's score of -1.58 indicating that Proteome Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Proteome Sciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Verici Dx 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative

Verici Dx (VRCI) Competitors

GBX 0.22 0.00 (0.00%)

As of 10/1/2026

Compare

VRCI vs. YGEN, AGL, GENI, PRM, and IDHC

Should you buy Verici Dx stock or one of its competitors? Verici Dx's main competitors and comparable companies include Yourgene Health (YGEN), ANGLE (AGL), GENinCode (GENI), Proteome Sciences (PRM), and Integrated Diagnostics (IDHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Verici Dx compare to Yourgene Health?

Verici Dx (LON:VRCI) and Yourgene Health (LON:YGEN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, Verici Dx had 1 more articles in the media than Yourgene Health. MarketBeat recorded 1 mentions for Verici Dx and 0 mentions for Yourgene Health. Yourgene Health's average media sentiment score of 0.00 beat Verici Dx's score of -1.58 indicating that Yourgene Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Verici Dx	Very Negative
Yourgene Health	Neutral

Verici Dx has higher earnings, but lower revenue than Yourgene Health. Verici Dx is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£3.66M	1.40	-£6.56M	-£0.90	N/A
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A

Verici Dx has a beta of 1.222, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Yourgene Health has a net margin of -27.55% compared to Verici Dx's net margin of -223.60%. Yourgene Health's return on equity of -27.06% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-223.60%	-127.57%	-26.14%
Yourgene Health	-27.55%	-27.06%	-6.71%

15.9% of Verici Dx shares are owned by institutional investors. Comparatively, 23.3% of Yourgene Health shares are owned by institutional investors. 1.2% of Verici Dx shares are owned by company insiders. Comparatively, 64.4% of Yourgene Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Yourgene Health beats Verici Dx on 8 of the 12 factors compared between the two stocks.

How does Verici Dx compare to ANGLE?

ANGLE (LON:AGL) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

In the previous week, ANGLE and ANGLE both had 1 articles in the media. ANGLE's average media sentiment score of 0.75 beat Verici Dx's score of -1.58 indicating that ANGLE is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANGLE	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verici Dx	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

ANGLE has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, meaning that its share price is 22% more volatile than the broader market.

Verici Dx has a net margin of -223.60% compared to ANGLE's net margin of -1,444.04%. Verici Dx's return on equity of -127.57% beat ANGLE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANGLE	-1,444.04%	-191.36%	-29.89%
Verici Dx	-223.60%	-127.57%	-26.14%

17.5% of ANGLE shares are held by institutional investors. Comparatively, 15.9% of Verici Dx shares are held by institutional investors. 2.7% of ANGLE shares are held by company insiders. Comparatively, 1.2% of Verici Dx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Verici Dx has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A
Verici Dx	£3.66M	1.40	-£6.56M	-£0.90	N/A

Summary

Verici Dx beats ANGLE on 8 of the 12 factors compared between the two stocks.

How does Verici Dx compare to GENinCode?

GENinCode (LON:GENI) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

11.4% of GENinCode shares are owned by institutional investors. Comparatively, 15.9% of Verici Dx shares are owned by institutional investors. 8.4% of GENinCode shares are owned by insiders. Comparatively, 1.2% of Verici Dx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GENinCode has a net margin of -202.42% compared to Verici Dx's net margin of -223.60%. Verici Dx's return on equity of -127.57% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENinCode	-202.42%	-481.34%	-63.99%
Verici Dx	-223.60%	-127.57%	-26.14%

GENinCode has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, meaning that its stock price is 22% more volatile than the broader market.

GENinCode has higher earnings, but lower revenue than Verici Dx. GENinCode is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENinCode	£3.08M	1.76	-£6.10M	-£2.08	N/A
Verici Dx	£3.66M	1.40	-£6.56M	-£0.90	N/A

In the previous week, GENinCode had 4 more articles in the media than Verici Dx. MarketBeat recorded 5 mentions for GENinCode and 1 mentions for Verici Dx. GENinCode's average media sentiment score of -0.31 beat Verici Dx's score of -1.58 indicating that GENinCode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GENinCode	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verici Dx	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

Summary

Verici Dx beats GENinCode on 7 of the 13 factors compared between the two stocks.

How does Verici Dx compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Proteome Sciences has a beta of 0.157, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, indicating that its stock price is 22% more volatile than the broader market.

In the previous week, Proteome Sciences and Proteome Sciences both had 1 articles in the media. Proteome Sciences' average media sentiment score of -0.71 beat Verici Dx's score of -1.58 indicating that Proteome Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Proteome Sciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Verici Dx	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

Proteome Sciences has higher revenue and earnings than Verici Dx. Proteome Sciences is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Proteome Sciences	£3.77M	1.13	-£4.08M	-£1.04	N/A
Verici Dx	£3.66M	1.40	-£6.56M	-£0.90	N/A

Proteome Sciences has a net margin of -61.46% compared to Verici Dx's net margin of -223.60%. Proteome Sciences' return on equity of 23.85% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Proteome Sciences	-61.46%	23.85%	-19.25%
Verici Dx	-223.60%	-127.57%	-26.14%

0.0% of Proteome Sciences shares are owned by institutional investors. Comparatively, 15.9% of Verici Dx shares are owned by institutional investors. 36.7% of Proteome Sciences shares are owned by insiders. Comparatively, 1.2% of Verici Dx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Proteome Sciences beats Verici Dx on 7 of the 12 factors compared between the two stocks.

How does Verici Dx compare to Integrated Diagnostics?

Verici Dx (LON:VRCI) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Integrated Diagnostics has a net margin of 16.49% compared to Verici Dx's net margin of -223.60%. Integrated Diagnostics' return on equity of 39.61% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-223.60%	-127.57%	-26.14%
Integrated Diagnostics	16.49%	39.61%	9.69%

Verici Dx has a beta of 1.222, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, suggesting that its stock price is 57% less volatile than the broader market.

15.9% of Verici Dx shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 1.2% of Verici Dx shares are held by insiders. Comparatively, 78.4% of Integrated Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Verici Dx had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for Verici Dx and 0 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 beat Verici Dx's score of -1.58 indicating that Integrated Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Verici Dx	Very Negative
Integrated Diagnostics	Neutral

Integrated Diagnostics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£3.66M	1.40	-£6.56M	-£0.90	N/A
Integrated Diagnostics	£9.17B	0.00	£4.01T	£263.00	0.00

Summary

Integrated Diagnostics beats Verici Dx on 9 of the 13 factors compared between the two stocks.

Get Verici Dx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

VRCI vs. The Competition

Export

Metric	Verici Dx	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£5.15M	£10.67B	£7.10B	£2.83B
Dividend Yield	N/A	1.45%	2.54%	6.26%
P/E Ratio	-0.25	31.75	273.96	366.33
Price / Sales	1.40	423.33	634.66	89,071.63
Price / Cash	1.31	27.32	27.22	27.89
Price / Book	0.05	6.87	11.09	6.96
Net Income	-£6.56M	£57.48B	£3.49B	£5.89B
7 Day Performance	7.14%	-0.29%	-2.30%	-0.62%
1 Month Performance	11.94%	7.02%	-7.05%	-1.07%
1 Year Performance	-69.18%	29.36%	5.65%	22.84%

Verici Dx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCI Verici Dx	N/A	GBX 0.23 flat	N/A	N/A	£5.15M	£3.66M	N/A	19	Gap Down
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253
AGL ANGLE	N/A	GBX 2.35 -11.3%	N/A	-14.5%	£7.58M	£2.62M	N/A	650	Gap Up
GENI GENinCode	N/A	GBX 0.89 -1.6%	N/A	-82.0%	£6.66M	£3.08M	N/A	2,300	Earnings Report Gap Down
PRM Proteome Sciences	N/A	GBX 1.21 -16.6%	N/A	-35.8%	£4.24M	£3.77M	N/A	240	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:VRCI) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verici Dx (VRCI) Competitors

VRCI vs. YGEN, AGL, GENI, PRM, and IDHC

How does Verici Dx compare to Yourgene Health?

Summary

How does Verici Dx compare to ANGLE?

Summary

How does Verici Dx compare to GENinCode?

Summary

How does Verici Dx compare to Proteome Sciences?

Summary

How does Verici Dx compare to Integrated Diagnostics?

Summary

New MarketBeat Followers Over Time

VRCI vs. The Competition

Verici Dx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verici Dx (VRCI) Competitors

VRCI vs. YGEN, AGL, GENI, PRM, and IDHC

How does Verici Dx compare to Yourgene Health?

Does the media refer more to VRCI or YGEN?

Which has higher valuation and earnings, VRCI or YGEN?

Which has more volatility & risk, VRCI or YGEN?

Is VRCI or YGEN more profitable?

Do institutionals and insiders have more ownership in VRCI or YGEN?

Summary

How does Verici Dx compare to ANGLE?

Does the media prefer AGL or VRCI?

Which has more volatility & risk, AGL or VRCI?

Is AGL or VRCI more profitable?

Do institutionals & insiders believe in AGL or VRCI?

Which has higher valuation and earnings, AGL or VRCI?

Summary

How does Verici Dx compare to GENinCode?

Do insiders and institutionals have more ownership in GENI or VRCI?

Is GENI or VRCI more profitable?

Which has more risk & volatility, GENI or VRCI?

Which has better valuation & earnings, GENI or VRCI?

Does the media favor GENI or VRCI?

Summary

How does Verici Dx compare to Proteome Sciences?

Which has more volatility & risk, PRM or VRCI?

Does the media favor PRM or VRCI?

Which has higher earnings and valuation, PRM or VRCI?

Is PRM or VRCI more profitable?

Do institutionals and insiders believe in PRM or VRCI?

Summary

How does Verici Dx compare to Integrated Diagnostics?

Is VRCI or IDHC more profitable?

Which has more risk & volatility, VRCI or IDHC?

Do insiders and institutionals believe in VRCI or IDHC?

Does the media favor VRCI or IDHC?

Which has higher earnings & valuation, VRCI or IDHC?

Summary

New MarketBeat Followers Over Time

VRCI vs. The Competition

Verici Dx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools